Proteozom İnhibitorleri
Özet
Proteozomlar, hem çekirdekte hem de sitoplazmada bulunarak hasarlı veya yanlış katlanmış hücresel proteinlerin peptidlere ayrılmasını sağlayan ve hücre döngüsü ile apoptozis gibi hayati süreçleri düzenleyen multikatalitik protein kompleksleridir. Malign hücreler, hızlı çoğalmaları ve genetik değişkenlikleri nedeniyle toksik protein birikimini önlemek için bu sisteme normal hücrelerden çok daha fazla bağımlıdır. Proteozom inhibitörleri, 26S proteozomunun katalitik beta alt birimlerine bağlanarak bu bozunma sürecini bloke eder; bu durum hücre içinde sitotoksik proteinlerin birikmesine, endoplazmik retikülüm stresine ve nihayetinde neoplastik hücrelerin programlanmış ölümüne yol açar. Klinik uygulamada ilk dönüm noktası, birinci kuşak ve geri dönüşümlü bir inhibitör olan bortezomibin multipl miyelom ve mantle hücreli lenfoma tedavisinde onay almasıyla yaşanmıştır. Bortezomibin nörotoksisite ve ilaç direnci gibi kısıtlılıklarını aşmak amacıyla, sonraki yıllarda daha yüksek afiniteli ve farklı uygulama yollarına sahip karfilzomib, ixazomib, oprozomib ve marizomib gibi ikinci kuşak moleküller geliştirilmiştir. Bu yeni ajanlar, özellikle immünomodülatör ilaçlar ve deksametazon ile kombine edildiklerinde, relaps veya dirençli hastalarda progresyonsuz ve genel sağkalım sürelerini anlamlı derecede artırarak modern hematolojik onkolojinin en güçlü terapötik stratejilerinden birini oluşturmuştur.
Proteasomes are large, multicatalytic protein complexes residing in both the nucleus and cytoplasm that degrade damaged or misfolded intracellular proteins into smaller peptides, playing a central role in cell cycle regulation and apoptosis avoidance. Due to their rapid proliferation and genetic instability, malignant cells are highly dependent on the ubiquitin-proteasome pathway to clear toxic proteins, making this system an ideal therapeutic target in oncology. Proteasome inhibitors exert their antitumor effects by binding to the proteolytic beta subunits of the 20S core within the 26S proteasome complex, thereby blocking protein degradation. This inhibition triggers a massive accumulation of cytotoxic proteins, inducing endoplasmic reticulum stress and driving rapidly dividing cancer cells toward apoptotic pathways. The therapeutic milestone began with bortezomib, a first-generation reversible inhibitor approved for multiple myeloma and mantle cell lymphoma. To overcome limitations like peripheral neuropathy and drug resistance associated with bortezomib, advanced second-generation inhibitors were developed, including carfilzomib, ixazomib, oprozomib, and marizomib. These newer agents offer distinct structural profiles, varying administration routes, and irreversible binding properties. When combined with immunomodulatory drugs and dexamethasone, they significantly prolong progression-free and overall survival in relapsed or refractory settings, establishing a cornerstone in hematologic malignancy management.
Referanslar
Almond, J.B., Cohen, G.M., The proteasome: a novel target for cancer chemotherapy, Leukemia, 16, 433-43, 2002.
Teicher, B.A.; Tomaszewski, J.E. Proteasome inhibitors. Biochem. Pharmacol. 2015, 96, 1–9.
Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017 Jul;14(7):417-433.
Nunes AT, Annunziata CM. Proteasome inhibitors: structure and function. Semin Oncol. 2017 Dec;44(6):377-380.
Anderson, K.C., The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma, J. Clin. Oncol., 30, 445-452, 2012.
Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003 May;29 Suppl 1:3-9.
Dick, L.R., Fleming, P.E., Building on bortezomib: second generation proteasome inhibitors as anti-cancer therapy, Drug Discovery Today, 15, 5-6, 2010.
Grzasko N, Morawska M, Hus M. Optimizing the treatment of patients with multiple myeloma and renal impairment. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):187-98.
Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma. New England Journal of Medicine. 2003;348(26):2609–17.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma. New England Journal of Medicine. 2005;352(24):2487–98.
Dimopoulos MA, Richardson PG, Schlag R et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009;27: 6086-6093.
Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Relapsed Multiple Myeloma: A Randomised, Phase 3, Non-Inferiority Study. Lancet Oncol. 2011;12(5):431-440.
Dou Q. P., Zonder J. A., Overview of Proteasome InhibitorBased Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System, Current Cancer Drug Targets, 14, 517-536, 2014.
Hungria VTM, Crusoé EQ, Bittencourt RI, Maiolino A, Magalhães RJP, Sobrinho JDN, Pinto JV, Fortes RC, Moreira ES, Tanaka PY. New proteasome inhibitors in the treatment of multiple myeloma. Hematol Transfus Cell Ther. 2019 Jan-Mar;41(1):76-83.
Dimopoulos MA, Moreau P, Palumbo A, et al. ENDEAVOR Investigators. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016; 17:27–38.
Stewart AK, Rajkumar SV, Dimopoulos MA, et al. ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372: 142–52.
Richardson PG, Kumar SK, Masszi T, et al. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol 2021.
Ninlaro (ixazomib) capsule package insert. Cambridge, MA: Takeda Pharmaceutical Company Limited; 2022 April.
Allegra A., Alonci A., Gerace D., Russo S., Innao V., Calabrò L., Musolino C., New orally active proteasome inhibitors in multiple myeloma, Leukemia Research, 38, 1-9, 2014.
Okazuka K, Ishida T. Proteasome inhibitors for multiple myeloma. Jpn J Clin Oncol. 2018 Sep 1;48(9):785-793.
R. Vij, M. Savona, D.S. Siegel, J.L. Kaufman, A. Et al. Clinical profile of single-agent oprozomib in patients (pts) with multiple myeloma (MM): updated results from a multicenter, open-label, dose escalation phase 1b/2 study Blood, 122 (2014), p. 653.
Richardson PG, Zimmerman TM, Hofmeister CC, et al. Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood. 2016 Jun 2;127(22):2693-700.
